CBS-003 - Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: CBS-003
• By: SAKAGUCHI, Kenta (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Japan)
• Co-author(s): Dr Kenta Sakaguchi (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Dr Takafumi Naito (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan / Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan)
  Dr Kohei Hoshikawa (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Dr Yukari Miyadera (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Dr Hironari Tanaka (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Dr Emi Nakatsugawa (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Dr Takahisa Furuta (First Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Dr Ken Sugimoto (First Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Dr Junichi Kawakami (Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan)
  
• Abstract:

  Introduction: Vonoprazan is a potassium-competitive acid blocker widely used for treating acid-related diseases such as gastroesophageal reflux disease and peptic ulcers. Vonoprazan has a superior efficacy in Helicobacter pylori eradication therapy compared to conventional proton pump inhibitors. In contrast, the patient factors that determine the ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login